Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18810151 | 0.95 | CTSB (0.38) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL11976114 | 0.94 | CTSB (0.37) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL11984211 | 0.94 | ADRB3 (0.41) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL1647041 | 0.94 | CTSB (0.36) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13798298 | 0.94 | CTSB (0.38) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13798303 | 0.94 | ADRB3 (0.40) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL1647040 | 0.94 | CTSB (0.36) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13798294 | 0.94 | CTSB (0.38) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13881884 | 0.94 | CTSB (0.38) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13610597 | 0.94 | CTSB (0.38) | CTSBADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637643-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING HCV INFECTIONS | HOFFMANN LA ROCHE (CH) | 2014-12-17 | — | — | EP | disclosed |
| US-20120114751-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING HCV INFECTIONS | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
| US-20100272682-A1 | METHOD FOR IMPROVING PHARMACOKINETICS | TRAN JONATHAN Q | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272682-A1 | METHOD FOR IMPROVING PHARMACOKINETICS | CYP3A43, CYP3A7, CYP7A1 | CTSB 886/4885ADRB3 634/4885ADRA2B 415/4885 |
| US-20120114751-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING HCV INFECTIONS | RNASE1, PNLIP, SERPINB1 | CTSB 30/4885ADRB3 2323/4885ADRA2B 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.